| This week's sponsor is RAPS. | |  | |
Featured Story | | | Friday, July 14, 2017 With investors clamoring for a deal to broaden its focus, Gilead could do a lot worse than make a bid for Incyte, say analysts at Leerink, though they admit it could be a pricey deal given Incyte's $28 billion enterprise value. |
|
|
Top Stories Friday, July 14, 2017 Akcea Therapeutics has set the terms for its $125 million IPO. The Ionis Pharmaceuticals spinout priced the IPO well below its target range but made up the shortfall by selling 62% more shares than it originally planned. Friday, July 14, 2017 Mayo Clinic and Nference have created an AI-driven R&D startup. The biotech, Qrativ, is starting life with $8.3 million in series A funds, access to its founders’ AI platform and clinical data and a remit to identify treatments for rare diseases. Thursday, July 13, 2017 A pair of Zika vaccines, given to mice before pregnancy, protected their offspring from Zika infection. The study is a step toward tangible protection for pregnant women, who risk fetal brain defects if they are exposed to the virus. Friday, July 14, 2017 Abbott has struck a deal to combine its FreeStyle Libre glucose sensing technology with Bigfoot Biomedical’s experimental insulin delivery device. The agreement sets Bigfoot up to start a pivotal trial of a version of its delivery system that incorporates the Abbott technology next year. Thursday, July 13, 2017 In this week's EuroBiotech Report, Novartis aces CAR-T panel, Shire hits Roche with injunction, Zealand files for IPO and more. Friday, July 14, 2017 A whistleblower lawsuit alleging Gilead used an unapproved API from China has been revived, Biocon and Mylan's Herceptin biosimilar is delayed in Europe due to plant issues, AstraZeneca is boosting production at its Australian site to meet rising respiratory demands in China, and more. Thursday, July 13, 2017 AstraZeneca CEO Pascal Soriot was said to be filling the CEO post at Teva, GSK poached Pfizer's medicinal sciences head Tony Wood, and Advaxis CEO O'Connor abruptly resigned. Plus more hirings, firings and retirings throughout the industry. | | | Shares in MorphoSys jumped after the FDA approved a Johnson & Johnson drug that will give it royalties. Article Innate Pharma completed the acquisition of an anti-C5aR antibody from Novo Nordisk. Statement Celltrion is looking to buy U.S. biotechs with pipelines of new drugs. Article (in Korean) | |
|
Resources Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: DocuSign When leading biopharma companies founded SAFE-BioPharma in 2005, it was with a vision of a not too distant future with major changes in the industry: the move to collaboration with many partners, make business processes fully electronic, and to take advantage of all of the benefits of online operations. Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Envigo Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
